Elsevier

Veterinary Microbiology

Volume 69, Issues 1–2, 1 September 1999, Pages 51-53
Veterinary Microbiology

Feline interferon-ω treatment on canine parvovirus infection

https://doi.org/10.1016/S0378-1135(99)00087-5Get rights and content

Abstract

Recombinant feline interferon-ω preparation (rFeIFN-ω, trade name: INTERCAT) showed good clinical efficacy on canine parvovirus infection both in an experimental trial with beagles, and in field trials.

Introduction

Recombinant feline interferon-ω preparation (rFeIFN-ω, trade name: INTERCAT) had been approved as the first veterinary anti-viral agent for feline calicivirus infection in 1994 and also approved as a treatment agent for canine parvovirus infection in 1997 in Japan (Yamamoto et al., 1990, Shimoda et al., 1997). A well-controlled study was designed to confirm the efficacy of rFeIFN-ω on canine varvovirus infection with the use of beagles as well as field clinical studies.

Section snippets

Interferon

The rFeIFN-ω is a lyophilized preparation for injection and was supplied from Toray Industries, (Ueda et al., 1993). One vial contains 10 million units (MU) of recombinant Feline Interferon-ω and it was dissolved in 1 ml of physiological saline just before use.

Viruses

The pathogenic strain of canine parvovirus (CPV) used in this study was supplied by Drs. Masami Mochizuki and Nobuyoshi Ishiguro of Tsukuba Central Laboratories of Kyoritsu Shoji. The pathogenic potential of this strain was confirmed in a

Results and discussion

A total of 36 beagles about four months old in three groups were used: 12 for the 1 MU group, 7 for the 5 MU group, 17 for the control group. The beagles were inoculated orally with CPV-2 suspension (10 ml/head of 106TCID50/ml). Beagles in the 1 MU and 5 MU group were injected intervenously with 1 MU/kg and 5 MU/kg of rFeIFN-ω, respectively, once a day for three consecutive days starting four days after the CPV inoculation. Physiological saline was administered to the control group. The administration

References (4)

There are more references available in the full text version of this article.

Cited by (38)

  • Antiviral Chemotherapy and Immunomodulatory Drugs

    2022, Greene's Infectious Diseases of the Dog and Cat, Fifth Edition
  • The Caliciviridae Family

    2022, Encyclopedia of Infection and Immunity
  • Interferon therapies in small animals

    2021, Veterinary Journal
    Citation Excerpt :

    In vitro, rFe IFN-ω inhibits CPV replication (Wang et al., 2020). In vivo, a number of studies have evaluated rFe IFN-ω for the treatment of canine parvoviral enteritis (Ishiwata et al., 1998; Minagawa et al., 1999; Martin et al., 2002; de Mari et al., 2003). All reported similar results (Table 7) and provide strong evidence to support the use of rFe IFN-ω in the treatment of canine parvoviral enteritis.

  • Update on Canine Parvoviral Enteritis

    2020, Veterinary Clinics of North America - Small Animal Practice
    Citation Excerpt :

    The role of interferons as a possible antiviral therapy has been investigated for dogs with CPV enteritis. Recombinant feline omega-interferon (1–5 × 106 IU/kg/d IV for 3 days) has been shown to decrease the incidence of fever, vomiting, diarrhea, and mortality and to improve appetite.92–95 The drug is not currently approved for use in the United States, but is available for use in Europe and Australia.

  • Design, biological activity and signaling pathway of bovine consensus omega interferon expressed in Pichia pastoris

    2019, Molecular Immunology
    Citation Excerpt :

    A single functional gene and at least two pseudogenes are present in human IFN-ω, but only a single pseudogene can be identified in mice IFN-ω (Hardy et al., 2004), while the IFN-ω family appears to have expanded in cats, which possess at least 10 variants on the basis of cDNA evidence (Hughes, 1995). IFN-ω has been approved as the veterinary antiviral agent for feline calicivirus infection and canine parvovirus infection (Minagawa et al., 1999; Vischer, 2006), as well as other disease (Domenech et al., 2011; Litzlbauer et al., 2014; Zetner et al., 2004). In bovine IFN-ω (BoIFN-ω), there are 24 potential IFN-ωs and at least 8 pseudogenes, which is significantly more compared with human and mouse IFN-ωs (Walker and Roberts, 2009).

  • Interferon-omega: Current status in clinical applications

    2017, International Immunopharmacology
    Citation Excerpt :

    There are several therapies used to treat CPV infections; however, many of them have drawbacks [50]. Reports suggest that rIFN-ω has a significant therapeutic effect on CPV-infected dogs [97,98]. For instance, it improved parvoviral clinical signs (such as pyrexia, vomiting, anorexia, and diarrhea), and reduced severe parvoviral enteritis and mortality in CPV infections.

View all citing articles on Scopus
View full text